Hyppigheden, rapporteret i kliniske forsøg, var 9, 4%, som følge af flergangsinjektioner af 0, 25 mg cetrorelix.
The frequency as reported in clinical trials was 9.4% following multiple injections of 0.25 mg cetrorelix.